Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773955 | 0.76 | CYP3A4 (0.39) | MEN1HCRTR1KMT2A | |
| SCHEMBL9979930 | 0.70 | ATM (0.55) | ATMMEN1HCRTR1KMT2A | |
| SCHEMBL22906899 | 0.68 | — | — | |
| SCHEMBL30885829 | 0.67 | ALDH1A1 (0.34) | USP2POLB | |
| SCHEMBL30136784 | 0.67 | CYP19A1 (0.33) | USP2POLB | |
| SCHEMBL24756084 | 0.67 | ALDH1A1 (0.34) | USP2POLB | |
| SCHEMBL24756083 | 0.66 | GPR35 (0.45) | USP2POLBMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL29224962 | 0.65 | USP2 (0.30) | USP2POLB | |
| Ammonia Solution, Strong SCHEMBL29225149 | 0.65 | USP2 (0.30) | USP2POLB | |
| SCHEMBL8140534 | 0.64 | ATM (0.53) | ATMMEN1HCRTR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157689-A1 | SUBSTITUTED INDOLOCARBAZOLES | XEROX CORPORATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-8110690-B2 | Substituted indolocarbazoles | XEROX CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090036689-A1 | SUBSTITUTED INDOLOCARBAZOLES | XEROX CORPORATION (US) | 2009-02-05 | — | — | US | disclosed |
| US-7456424-B2 | Thin film transistors including indolocarbozoles | XEROX CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036689-A1 | SUBSTITUTED INDOLOCARBAZOLES | HTR3C, HTR3A, AANAT | USP2 3423/4885POLB 3546/4885ATM 639/4885 |
| US-20120157689-A1 | SUBSTITUTED INDOLOCARBAZOLES | HTR3C, HTR3A, AANAT | USP2 3423/4885POLB 3546/4885ATM 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.